Skip to content

Clinical observation of remazolam besylate used in laparoscopic comprehensive staging surgery of endometrial cancer in elderly patients

Clinical observation of remazolam besylate used in laparoscopic comprehensive staging surgery of endometrial cancer in elderly patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042679
Enrollment
Unknown
Registered
2021-01-26
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic comprehensive staging of endometrial cancer in elderly patients

Interventions

R group:Group R was given remazolam besylate during the induction and maintenance periods of anesthesia
P group:Group P was given propofol during the induction and maintenance of anesthesia

Sponsors

Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Select Zhuhai Peoples Hospital from January 2021 to January 2022 for elderly endometrial cancer patients, 80 patients eligible for elective laparoscopic full staging of endometrial cancer, aged > 65 years, ASA I-II grade, BMI: 1828kg/m2, can be scored with the Mini Mental State Examination Scale (MMSE).

Exclusion criteria

Exclusion criteria: (1) Patients with severe hypertension, neuropsychiatric diseases and heart, lung, liver and kidney function abnormalities; (2) Patients with severe sensory organ defects (such as vision and hearing impairment) or unable to communicate with the interviewers for other reasons to affect the test; (3) Taking sedatives, antidepressants, alcoholism; patients with known allergy to rimazolom toluenesulfonate and midazolam; (4) Preoperative MMSE score <= 17 and patients who do not agree to be selected or voluntarily withdraw their informed consent; (5) Intraoperative bleeding was greater than 500ml.

Design outcomes

Primary

MeasureTime frame
blood pressure;Pulse Oxygen Saturation (SPO);heart?rate(HR);Operation?time;Intraoperative?blood?loss;Remazolam besylate dosage;Propofol?dosage;Infusion volume and blood transfusion volume;Recovery?time;Extubation time;MMSE score;Urine volume;Ephedrine;atropine;TNF-a;???-6;S100ß protein;

Countries

China

Contacts

Public ContactLiang Genqiang

Zhuhai People's Hospital (Zhuhai Hospital affiliated with Jinan University)

2330718380@qq.com+86 13926935089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026